Across TCGA pan-cancer cohorts, CSNK1E Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CSNK1E data layer compared with 29 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher CSNK1E Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CSNK1E expression acts as an unfavorable survival marker.

LIHC, HNSC, and UCEC are the cancer types where CSNK1E Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	II,III,IV	0.092	0.716	<.001	30	view →
HNSC	DFS	Median	II,III,IV	0.201	0.666	.003	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: CSNK1E tumor-vs-normal RNA expression · all CSNK1E data types